Dr. M. Mansoor is a urologist with over four decades of experience in surgical medicine and urological care. Born in Pakistan, Dr. Mansoor brings extensive clinical expertise to his role as a medical content author.
Dr. Mansoor pursued his medical education in the United Kingdom, where he developed a strong foundation in clinical medicine and surgical techniques. His professional qualifications include MBBS, FCPS (Surgery), and FCPS (Urology).
As a urologist, Dr. Mansoor specializes in the diagnosis and treatment of conditions affecting the urinary system and male reproductive organs. His expertise encompasses from routine procedures to complex surgical interventions involving the kidneys, bladder, prostate, and other urogenital structures. Dr. Mansoor has made significant contributions to medical education through his authorship of medical content.
Dr. Mansoor earned his MBBS from a UK medical institution and completed his Fellowship of the College of Physicians and Surgeons in both Surgery and Urology.
William K. McVicar, Ph.D., was appointed CEO in July 2017 after joining Flex Pharma in April 2017 as President of Research & Development. Dr. McVicar brings to Flex Pharma approximately 30 years of clinical development experience. Prior to joining Flex Pharma, Dr. McVicar served as Executive Vice President of Pharmaceutical Development, Chief Scientific Officer, and President during his tenure at Inotek. As Vice President of Development Operations at Sepracor, he oversaw the development, FDA review, and approval of multiple NDAs and SNDAs, including BROVANA®, XOPENEX MDI®, and XOPENEX’s pediatric approval, which were each approved in a single 10-month review cycle. Prior to Sepracor, Dr. McVicar held various positions of increasing responsibility at Sandoz, Novartis and Rhone Poulenc Rorer.
Dr. McVicar earned his B.S. in Chemistry from the State University of New York College at Oneonta and his Ph.D. in Chemistry from the University of Vermont.
John McCabe joined Flex Pharma from ARIAD Pharmaceuticals, where he was Vice President and Chief Accounting Officer. Previously, he served as Vice President and Corporate Controller at Charles River Associates, where he was responsible for all aspects of global financial accounting, planning, and reporting. Prior to Charles River Associates, he was Director and strategic business unit Controller at Biogen Idec, managing all accounting and government pricing functions for the U.S. commercial business, including Avonex, Tysabri, and Rituxan. Mr. McCabe started his career at Arthur Andersen & Co., where he advanced to an Audit Manager and he later held financial positions at two technology companies.
Mr. McCabe holds B.S. degrees in accounting and management information systems from Babson College, and an M.B.A from the University of Massachusetts at Amherst.